Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $51.00 at Raymond James

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its price objective increased by research analysts at Raymond James from $34.00 to $51.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Raymond James' target price points to a potential upside of 115.83% from the company's current price.

Several other research analysts also recently commented on the company. Stifel Nicolaus initiated coverage on Dianthus Therapeutics in a report on Thursday, February 15th. They issued a "buy" rating and a $44.00 target price on the stock. Wedbush boosted their target price on Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an "outperform" rating in a report on Friday, March 22nd. Finally, Jefferies Financial Group boosted their target price on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $42.40.

Dianthus Therapeutics Stock Up 1.2 %

NASDAQ DNTH traded up $0.29 during trading on Thursday, reaching $23.63. 119,754 shares of the company traded hands, compared to its average volume of 143,247. The stock's 50 day moving average price is $25.82 and its two-hundred day moving average price is $17.11. Dianthus Therapeutics has a 1-year low of $6.58 and a 1-year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($1.11) by $0.40. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.73 million. Equities analysts forecast that Dianthus Therapeutics will post -1.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DNTH. Tower Research Capital LLC TRC bought a new position in Dianthus Therapeutics in the 4th quarter worth approximately $25,000. Citigroup Inc. bought a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $53,000. Dimensional Fund Advisors LP bought a new position in Dianthus Therapeutics in the 4th quarter worth approximately $153,000. Northern Trust Corp bought a new position in Dianthus Therapeutics in the 4th quarter worth approximately $159,000. Finally, Acadian Asset Management LLC bought a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $303,000. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.